

Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011

Description: Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011

Summary

Global Markets Direct's, 'Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011', provides an overview of the Acromegaly And Gigantism (Growth Hormone Disorders) therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly And Gigantism (Growth Hormone Disorders), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acromegaly And Gigantism (Growth Hormone Disorders). 'Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acromegaly And Gigantism (Growth Hormone Disorders).
- A review of the Acromegaly And Gigantism (Growth Hormone Disorders) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acromegaly And Gigantism (Growth Hormone Disorders) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acromegaly And Gigantism (Growth Hormone Disorders).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acromegaly And Gigantism (Growth Hormone Disorders) pipeline depth and focus of Acromegaly And Gigantism (Growth Hormone Disorders) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures

Introduction
Global Markets Direct Report Coverage
Acromegaly And Gigantism (Growth Hormone Disorders) Overview
Therapeutics Development
An Overview of Pipeline Products for Acromegaly And Gigantism (Growth Hormone Disorders)
Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics under Development by Companies
Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics - Products under Development by Companies
Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics Development
Glide Pharmaceutical Technologies Limited
Ambrilia Biopharma Inc.
Teijin Pharma Limited
Novartis AG
Alchemia Limited
Evotec Aktiengesellschaft
Antisense Therapeutics Limited
Asterion Ltd
Camurus AB
Syntaxin Ltd
Oakwood Laboratories L.L.C.
Peptron, Inc.
Endo Pharmaceuticals Inc.
Chiasma (Israel) Ltd.
Acromegaly And Gigantism (Growth Hormone Disorders) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C2L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octreotide Implant - Drug Profile
Product Description
Mechanism of Action
ITM-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Somatuline Autogel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acromegaly And Gigantism (Growth Hormone Disorders) Therapeutics - Discontinued Products
Acromegaly And Gigantism (Growth Hormone Disorders) - Featured News
Jun 28, 2010: Chiasma Receives FDA's Orphan Drug Designation For Octreolin For Oral Treatment Of

Acromegaly

Jun 14, 2010: Chiasma Reports Successful Oral Delivery Of Octreolin In Clinical Study

Mar 29, 2010: Versartis To Present New Data On VRS-317 At International Congress On Endocrinology

Oct 12, 2009: ATL1103 On Track To Move Into Clinical Development

Sep 23, 2009: Versartis Presents Preclinical Data For VRS-317

Jul 24, 2009: Ambrilia Biopharma Inc Announced Termination Of Study 303 And Update On C2L Development

Jun 19, 2009: Novartis' Acromegaly Drug Pasireotide Shows Promise

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products Under Development for Acromegaly And Gigantism (Growth Hormone Disorders), Q1 2011

Products under Development for Acromegaly And Gigantism (Growth Hormone Disorders) – Comparative Analysis, Q1 2011

Comparative Analysis by Late Stage Development, Q1 2011

Comparative Analysis by Mid Clinical Stage Development, Q1 2011

Comparative Analysis by Early Clinical Stage Development, Q1 2011

Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011

Glide Pharmaceutical Technologies Limited, 2011

Ambrilia Biopharma Inc., 2011

Teijin Pharma Limited, 2011

Novartis AG, 2011

Alchemia Limited, 2011

Evotec Aktiengesellschaft, 2011

Antisense Therapeutics Limited, 2011

Asterion Ltd, 2011

Camurus AB, 2011

Syntaxin Ltd, 2011

Oakwood Laboratories L.L.C., 2011

Peptron, Inc., 2011

Endo Pharmaceuticals Inc., 2011

Chiasma (Israel) Ltd., 2011

Assessment by Monotherapy Products, Q1 2011

Assessment by Stage and Route of Administration, Q1 2011

Assessment by Molecule Type, Q1 2011

Discontinued Products

List of Figures

Number of Products under Development for Acromegaly And Gigantism (Growth Hormone Disorders), Q1 2011

Products under Development for Acromegaly And Gigantism (Growth Hormone Disorders) – Comparative Analysis, Q1 2011

Products under Development by Companies, Q1 2011

Products under Investigation by Universities/Institutes, Q1 2011

Late Stage Products, Q1 2011

Mid Clinical Stage Products, Q1 2011

Early Clinical Stage Products, Q1 2011

Discovery and Pre-Clinical Stage Products, Q1 2011

Assessment by Monotherapy Products, Q1 2011

Assessment by Route of Administration, Q1 2011

Assessment by Stage and Route of Administration, Q1 2011

Assessment by Molecule Type, Q1 2011

Assessment by Stage and Molecule Type, Q1 2011

RESEARCHANDMARKETS

Ordering: Order Online - <http://www.researchandmarkets.com/reports/1590141/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Acromegaly And Gigantism (Growth Hormone Disorders) - Pipeline Review, Q1 2011
Web Address: <http://www.researchandmarkets.com/reports/1590141/>
Office Code: OC8DIOORTSRQPV

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 369
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 738
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 1107

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVV Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World